Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WP 1220

Next Previous
Search
Drug Profile

WP 1220

Alternative Names: MOL-4239; WP-1220

Latest Information Update: 17 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Amides; Antineoplastics; Antipsoriatics; Halogenated hydrocarbons; Nitriles; Pyridines; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cutaneous T-cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 Mar 2023 Moleculin has patent protection in China, Eurasia, Europe, Japan, Mexico, New Zealand, Singapore, Ukraine and USA
  • 12 Apr 2022 Phase-I/II clinical trials in Cutaneous T-cell lymphoma in Poland (Topical) (WPD Pharmaceuticals pipeline, April 2022)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma in Poland (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top